BIOPHEN™ FVIII Variant
We're always working hard to give our customers as much information on products and the best price possible. If you need any assistance or would like a quote please contact us and we will be happy to help
BIOPHEN™ FVIII Variant (227102) is a Chromogenic method for the in vitro quantitative determination of Factor VIII (FVIII) activity, in human citrated plasma or FVIII concentrates, using an automated method. In vitro diagnostic use only. Manufactured by HYPHEN BioMed.
The BIOPHEN™ Factor VIII variant method involves the chromogenic assay of FVIII cofactor. In the presence of phospholipids (PLPs) and calcium, FVIII, activated by thrombin, forms an enzyme complex with Factor IXa, which activates Factor X. The resulting Factor Xa hydrolyzes the chromogenic substrate, leading to the release of paranitroaniline (pNa). The amount of pNA released (measured by absorbance at 405 nm) is directly proportional to the concentration of FVIII in the specimen (Factor IXa, Thrombin and Factor X are in constant excess amount). The BIOPHEN™ FVIII variant kit is a variant method of BIOPHEN™ FVIII (221402 / 221406) where FX is from bovine origin and which is insensitive to Emicizumab.
